华纳药厂(688799.SH)参股公司收到ZG-002片Ⅰ期临床研究报告

Core Viewpoint - Warner Pharmaceuticals (688799.SH) announced that its associate company, Shanghai Zhigen Pharmaceutical Technology Co., Ltd., has completed Phase I clinical trials for ZG-002, a novel drug for autoimmune diseases, with the approval of the National Medical Products Administration [1] Group 1: Clinical Trial Details - ZG-002 is a first-in-class new drug developed by Zhigen Pharmaceutical, currently intended for the treatment of moderate to severe plaque psoriasis [1] - The primary objective of the clinical trial was to evaluate the safety, tolerability, pharmacokinetics, and food effects of ZG-002 in healthy adult subjects [1] - The trial results indicate that ZG-002 has good safety and tolerability under the current dosing regimen, with clear pharmacokinetic characteristics [1] Group 2: Future Research Implications - The clinical data obtained from this study supports the further exploration of ZG-002 in subsequent clinical research involving patient populations [1]